CY1118966T1 - Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος - Google Patents
Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματοςInfo
- Publication number
- CY1118966T1 CY1118966T1 CY20171100240T CY171100240T CY1118966T1 CY 1118966 T1 CY1118966 T1 CY 1118966T1 CY 20171100240 T CY20171100240 T CY 20171100240T CY 171100240 T CY171100240 T CY 171100240T CY 1118966 T1 CY1118966 T1 CY 1118966T1
- Authority
- CY
- Cyprus
- Prior art keywords
- prevention
- treatment
- central nervous
- nervous systems
- new compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει νέες ενώσεις, καθώς και συνθέσεις και μεθόδους που χρησιμοποιούνται το ίδιο για την πρόληψη και/ή θεραπεία εκφυλιστικών διαταραχών του κεντρικού νευρικού συστήματος. Ειδικότερα, η παρούσα εφεύρεση παρέχει μεθόδους για την πρόληψη και/ή θεραπεία της νόσου του Parkinson.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25280309P | 2009-10-19 | 2009-10-19 | |
| PCT/US2010/051447 WO2011049736A1 (en) | 2009-10-19 | 2010-10-05 | Novel compositions for preventing and/or treating degenerative disorders of the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118966T1 true CY1118966T1 (el) | 2018-01-10 |
Family
ID=43879775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100240T CY1118966T1 (el) | 2009-10-19 | 2017-02-22 | Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8604206B2 (el) |
| EP (2) | EP3143875B1 (el) |
| JP (2) | JP5805649B2 (el) |
| KR (3) | KR101769396B1 (el) |
| CN (2) | CN102655747A (el) |
| AR (1) | AR078606A1 (el) |
| AU (3) | AU2010308396B2 (el) |
| BR (1) | BR112012009121A2 (el) |
| CA (1) | CA2778348C (el) |
| CY (1) | CY1118966T1 (el) |
| DK (1) | DK2490532T3 (el) |
| ES (2) | ES2617192T3 (el) |
| HK (1) | HK1219724A1 (el) |
| HR (1) | HRP20170236T1 (el) |
| HU (1) | HUE033116T2 (el) |
| IL (1) | IL219160B (el) |
| LT (1) | LT2490532T (el) |
| MX (2) | MX340807B (el) |
| PL (1) | PL2490532T3 (el) |
| PT (1) | PT2490532T (el) |
| RS (1) | RS55679B1 (el) |
| RU (2) | RU2015147509A (el) |
| SG (1) | SG10201507159XA (el) |
| SI (1) | SI2490532T1 (el) |
| SM (1) | SMT201700105B (el) |
| TW (1) | TWI642434B (el) |
| WO (1) | WO2011049736A1 (el) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016103139A (ru) | 2009-10-19 | 2018-11-22 | Амикус Терапьютикс, Инк. | Новые композиции для предупреждения и/или лечения лизосомных болезней накопления |
| CA2778348C (en) | 2009-10-19 | 2022-08-23 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating degenerative disorders of the central nervous system |
| EP2591823A1 (en) * | 2011-11-11 | 2013-05-15 | Biologische Heilmittel Heel GmbH | Composition for treating or preventing neurodegenerative disorders |
| EP2831043B1 (en) * | 2012-03-27 | 2022-07-27 | Amicus Therapeutics, Inc. | Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system |
| US9796680B2 (en) | 2013-12-23 | 2017-10-24 | Alectos Therapeutics Inc. | Glucocerebrosidase modulators and uses thereof |
| US10179128B2 (en) * | 2015-08-31 | 2019-01-15 | Amicus Therapeutics, Inc. | Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system |
| CN110573492A (zh) | 2017-04-25 | 2019-12-13 | 阿米库斯治疗学公司 | 用于预防和/或治疗中枢神经系统退行性失调和/或溶酶体贮积失调的新颖组合物 |
| RU2676956C1 (ru) * | 2017-08-25 | 2019-01-11 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Антитела для связывания имиглюцеразы и их применение в аффинной хроматографии |
| KR101991276B1 (ko) | 2018-01-19 | 2019-06-21 | 전남대학교산학협력단 | 신규 균주 페니실리움 아쿠아티쿰 및 이를 이용한 퇴행성 뇌질환 치료제 |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| US20240252418A1 (en) * | 2023-01-31 | 2024-08-01 | Bioeutectics Corporation | Additives (Adjuvants, Anti Freezing Agents, Antimicrobial and Antioxidants) in Natural Deep Eutectic Solvents and Mixtures |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| ATE156344T1 (de) | 1991-04-25 | 1997-08-15 | Univ Brown Res Found | Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| CA2145418A1 (en) | 1992-09-29 | 1994-04-14 | John S. Patton | Pulmonary delivery of active fragments of parathyroid hormone |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| WO1995024391A1 (en) | 1994-03-09 | 1995-09-14 | Novo Nordisk A/S | Piperidines and pyrrolidines |
| FR2718357B1 (fr) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Perfectionnements apportés à un dispositif d'injection par jet sans aiguille. |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| TW498067B (en) * | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| JP2006507359A (ja) * | 2002-10-28 | 2006-03-02 | ノボ・ノルデイスク・エー／エス | 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用 |
| US20040082641A1 (en) | 2002-10-28 | 2004-04-29 | Rytved Klaus Asger | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
| US7446098B2 (en) | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
| EP1711197A4 (en) | 2003-12-23 | 2008-11-05 | Musc Found For Res Dev | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR DISORDERS |
| PT1860101E (pt) * | 2006-05-24 | 2011-07-12 | Amicus Therapeutics Inc | Sal de tartrato da isofagomina e métodos de uso |
| ES2364586T3 (es) * | 2006-05-24 | 2011-09-07 | Amicus Therapeutics, Inc. | Sal tartrato de isofagomina y métodos de uso. |
| JP5303458B2 (ja) * | 2006-06-23 | 2013-10-02 | アミークス セラピューティックス インコーポレイテッド | β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法 |
| CA2685332A1 (en) | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| WO2010015816A2 (en) | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| JP5645918B2 (ja) | 2009-04-09 | 2014-12-24 | アミカス セラピューティックス インコーポレイテッド | リソソーム蓄積障害の予防および／または治療方法 |
| ES2505243T3 (es) | 2009-04-09 | 2014-10-09 | Amicus Therapeutics, Inc. | Agentes terapéuticos para prevenir y/o tratar trastornos degenerativos del sistema nervioso central |
| RU2016103139A (ru) * | 2009-10-19 | 2018-11-22 | Амикус Терапьютикс, Инк. | Новые композиции для предупреждения и/или лечения лизосомных болезней накопления |
| CA2778348C (en) | 2009-10-19 | 2022-08-23 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating degenerative disorders of the central nervous system |
| CA2778049C (en) * | 2009-10-19 | 2018-12-04 | Amicus Therapeutics, Inc. | Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
| KR102023720B1 (ko) | 2012-09-03 | 2019-09-20 | 엘지이노텍 주식회사 | 보이스 코일 모터 |
-
2010
- 2010-10-05 CA CA2778348A patent/CA2778348C/en active Active
- 2010-10-05 US US12/898,112 patent/US8604206B2/en active Active
- 2010-10-05 KR KR1020127012936A patent/KR101769396B1/ko active IP Right Grant
- 2010-10-05 ES ES10825396.4T patent/ES2617192T3/es active Active
- 2010-10-05 EP EP16191218.3A patent/EP3143875B1/en active Active
- 2010-10-05 WO PCT/US2010/051447 patent/WO2011049736A1/en active Application Filing
- 2010-10-05 ES ES16191218T patent/ES2814178T3/es active Active
- 2010-10-05 AU AU2010308396A patent/AU2010308396B2/en not_active Ceased
- 2010-10-05 SI SI201031401A patent/SI2490532T1/sl unknown
- 2010-10-05 PL PL10825396T patent/PL2490532T3/pl unknown
- 2010-10-05 KR KR1020177037220A patent/KR101880411B1/ko active IP Right Grant
- 2010-10-05 BR BR112012009121A patent/BR112012009121A2/pt not_active Application Discontinuation
- 2010-10-05 PT PT108253964T patent/PT2490532T/pt unknown
- 2010-10-05 MX MX2012004548A patent/MX340807B/es active IP Right Grant
- 2010-10-05 RS RS20170153A patent/RS55679B1/sr unknown
- 2010-10-05 CN CN2010800566279A patent/CN102655747A/zh active Pending
- 2010-10-05 SG SG10201507159XA patent/SG10201507159XA/en unknown
- 2010-10-05 DK DK10825396.4T patent/DK2490532T3/en active
- 2010-10-05 CN CN201510783936.0A patent/CN105367485B/zh not_active Expired - Fee Related
- 2010-10-05 EP EP10825396.4A patent/EP2490532B1/en active Active
- 2010-10-05 KR KR1020177022493A patent/KR101813988B1/ko active IP Right Grant
- 2010-10-05 LT LTEP10825396.4T patent/LT2490532T/lt unknown
- 2010-10-05 MX MX2016000153A patent/MX368459B/es unknown
- 2010-10-05 JP JP2012535221A patent/JP5805649B2/ja active Active
- 2010-10-05 HU HUE10825396A patent/HUE033116T2/en unknown
- 2010-10-05 RU RU2015147509A patent/RU2015147509A/ru unknown
- 2010-10-05 RU RU2012120759/04A patent/RU2581058C2/ru active
- 2010-10-12 TW TW099134782A patent/TWI642434B/zh not_active IP Right Cessation
- 2010-10-12 AR ARP100103715A patent/AR078606A1/es unknown
-
2012
- 2012-04-15 IL IL219160A patent/IL219160B/en not_active IP Right Cessation
-
2013
- 2013-03-01 HK HK16107625.0A patent/HK1219724A1/zh unknown
- 2013-11-19 US US14/084,131 patent/US9409862B2/en active Active
-
2015
- 2015-03-30 JP JP2015069784A patent/JP6258245B2/ja active Active
-
2016
- 2016-06-08 AU AU2016203817A patent/AU2016203817B2/en not_active Ceased
- 2016-07-22 US US15/217,217 patent/US20160326114A1/en not_active Abandoned
-
2017
- 2017-02-13 HR HRP20170236TT patent/HRP20170236T1/hr unknown
- 2017-02-16 SM SM201700105T patent/SMT201700105B/it unknown
- 2017-02-22 CY CY20171100240T patent/CY1118966T1/el unknown
- 2017-12-07 AU AU2017272296A patent/AU2017272296B2/en not_active Ceased
-
2018
- 2018-06-01 US US15/995,813 patent/US10421724B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118966T1 (el) | Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος | |
| AU2018236800B2 (en) | DNA-PK inhibitors | |
| CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
| CY1118452T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
| EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
| UA115983C2 (uk) | Інгібітори днк-пк | |
| MX2020012825A (es) | Compuestos multiciclicos y metodos de uso de los mismos. | |
| EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
| PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| EA201290894A1 (ru) | Азетидиновые производные пиперидин-4-ила как ингибиторы jak1 | |
| MA32889B1 (fr) | Composes de pyrazine comme inhibiteurs de phosphodiesterase 10 | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| CR20110103A (es) | Heteroarilos sustituidos | |
| PH12017500841B1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| MX2011008645A (es) | Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa. | |
| CY1116158T1 (el) | Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| MA32416B1 (fr) | 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation | |
| MX2013002295A (es) | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. |